vs

Side-by-side financial comparison of ALAMO GROUP INC (ALG) and Axsome Therapeutics, Inc. (AXSM). Click either name above to swap in a different company.

ALAMO GROUP INC is the larger business by last-quarter revenue ($373.6M vs $196.0M, roughly 1.9× Axsome Therapeutics, Inc.). ALAMO GROUP INC runs the higher net margin — 4.2% vs -14.6%, a 18.7% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs -3.0%). ALAMO GROUP INC produced more free cash flow last quarter ($69.9M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs -6.3%).

The Alamo Drafthouse Cinema is an American cinema chain founded in 1997 in Austin, Texas, which is famous for serving dinner and drinks during the film, as well as its strict policy of requiring its audiences to maintain proper cinema-going etiquette. Sony Pictures Experiences acquired the chain in June 2024.

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

ALG vs AXSM — Head-to-Head

Bigger by revenue
ALG
ALG
1.9× larger
ALG
$373.6M
$196.0M
AXSM
Growing faster (revenue YoY)
AXSM
AXSM
+68.1% gap
AXSM
65.0%
-3.0%
ALG
Higher net margin
ALG
ALG
18.7% more per $
ALG
4.2%
-14.6%
AXSM
More free cash flow
ALG
ALG
$88.6M more FCF
ALG
$69.9M
$-18.7M
AXSM
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
61.7%
-6.3%
ALG

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ALG
ALG
AXSM
AXSM
Revenue
$373.6M
$196.0M
Net Profit
$15.5M
$-28.6M
Gross Margin
22.7%
Operating Margin
6.0%
-13.8%
Net Margin
4.2%
-14.6%
Revenue YoY
-3.0%
65.0%
Net Profit YoY
-44.8%
61.9%
EPS (diluted)
$1.28
$-0.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALG
ALG
AXSM
AXSM
Q4 25
$373.6M
$196.0M
Q3 25
$420.0M
$171.0M
Q2 25
$419.1M
$150.0M
Q1 25
$390.9M
$121.5M
Q4 24
$385.3M
$118.8M
Q3 24
$401.3M
$104.8M
Q2 24
$416.3M
$87.2M
Q1 24
$425.6M
$75.0M
Net Profit
ALG
ALG
AXSM
AXSM
Q4 25
$15.5M
$-28.6M
Q3 25
$25.4M
$-47.2M
Q2 25
$31.1M
$-48.0M
Q1 25
$31.8M
$-59.4M
Q4 24
$28.1M
$-74.9M
Q3 24
$27.4M
$-64.6M
Q2 24
$28.3M
$-79.3M
Q1 24
$32.1M
$-68.4M
Gross Margin
ALG
ALG
AXSM
AXSM
Q4 25
22.7%
Q3 25
24.2%
Q2 25
25.8%
Q1 25
26.3%
Q4 24
23.8%
Q3 24
25.1%
Q2 24
26.0%
Q1 24
26.2%
Operating Margin
ALG
ALG
AXSM
AXSM
Q4 25
6.0%
-13.8%
Q3 25
8.9%
-27.0%
Q2 25
11.2%
-24.5%
Q1 25
11.4%
-46.9%
Q4 24
8.9%
-61.1%
Q3 24
10.0%
-59.8%
Q2 24
10.4%
-89.5%
Q1 24
11.0%
-89.7%
Net Margin
ALG
ALG
AXSM
AXSM
Q4 25
4.2%
-14.6%
Q3 25
6.0%
-27.6%
Q2 25
7.4%
-32.0%
Q1 25
8.1%
-48.9%
Q4 24
7.3%
-63.1%
Q3 24
6.8%
-61.7%
Q2 24
6.8%
-91.0%
Q1 24
7.5%
-91.1%
EPS (diluted)
ALG
ALG
AXSM
AXSM
Q4 25
$1.28
$-0.55
Q3 25
$2.10
$-0.94
Q2 25
$2.57
$-0.97
Q1 25
$2.64
$-1.22
Q4 24
$2.33
$-1.54
Q3 24
$2.28
$-1.34
Q2 24
$2.35
$-1.67
Q1 24
$2.67
$-1.44

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALG
ALG
AXSM
AXSM
Cash + ST InvestmentsLiquidity on hand
$309.7M
$322.9M
Total DebtLower is stronger
$190.7M
Stockholders' EquityBook value
$1.1B
$88.3M
Total Assets
$1.6B
$689.8M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALG
ALG
AXSM
AXSM
Q4 25
$309.7M
$322.9M
Q3 25
$244.8M
$325.3M
Q2 25
$201.8M
$303.0M
Q1 25
$200.3M
$300.9M
Q4 24
$197.3M
$315.4M
Q3 24
$140.0M
$327.3M
Q2 24
$118.5M
$315.7M
Q1 24
$121.8M
$331.4M
Total Debt
ALG
ALG
AXSM
AXSM
Q4 25
$190.7M
Q3 25
$194.4M
Q2 25
$198.1M
Q1 25
$201.8M
Q4 24
$205.5M
Q3 24
$209.2M
Q2 24
$278.6M
Q1 24
$306.5M
Stockholders' Equity
ALG
ALG
AXSM
AXSM
Q4 25
$1.1B
$88.3M
Q3 25
$1.1B
$73.7M
Q2 25
$1.1B
$73.1M
Q1 25
$1.1B
$53.2M
Q4 24
$1.0B
$57.0M
Q3 24
$1.0B
$92.9M
Q2 24
$979.7M
$102.9M
Q1 24
$956.6M
$144.0M
Total Assets
ALG
ALG
AXSM
AXSM
Q4 25
$1.6B
$689.8M
Q3 25
$1.6B
$669.3M
Q2 25
$1.6B
$639.8M
Q1 25
$1.5B
$596.7M
Q4 24
$1.5B
$568.5M
Q3 24
$1.5B
$561.5M
Q2 24
$1.5B
$548.2M
Q1 24
$1.5B
$545.7M
Debt / Equity
ALG
ALG
AXSM
AXSM
Q4 25
0.17×
Q3 25
0.17×
Q2 25
0.18×
Q1 25
0.19×
Q4 24
0.20×
Q3 24
0.21×
Q2 24
0.28×
Q1 24
0.32×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALG
ALG
AXSM
AXSM
Operating Cash FlowLast quarter
$75.1M
$-18.7M
Free Cash FlowOCF − Capex
$69.9M
$-18.7M
FCF MarginFCF / Revenue
18.7%
-9.6%
Capex IntensityCapex / Revenue
1.4%
0.0%
Cash ConversionOCF / Net Profit
4.84×
TTM Free Cash FlowTrailing 4 quarters
$146.9M
$-93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALG
ALG
AXSM
AXSM
Q4 25
$75.1M
$-18.7M
Q3 25
$65.5M
$1.0M
Q2 25
$22.7M
$-32.4M
Q1 25
$14.2M
$-43.4M
Q4 24
$79.1M
$-26.2M
Q3 24
$96.3M
$-18.6M
Q2 24
$33.2M
$-30.1M
Q1 24
$1.1M
$-53.5M
Free Cash Flow
ALG
ALG
AXSM
AXSM
Q4 25
$69.9M
$-18.7M
Q3 25
$53.1M
$988.0K
Q2 25
$15.7M
$-32.4M
Q1 25
$8.2M
$-43.7M
Q4 24
$73.1M
$-26.2M
Q3 24
$88.4M
$-18.7M
Q2 24
$28.8M
$-30.2M
Q1 24
$-5.5M
$-53.6M
FCF Margin
ALG
ALG
AXSM
AXSM
Q4 25
18.7%
-9.6%
Q3 25
12.6%
0.6%
Q2 25
3.8%
-21.6%
Q1 25
2.1%
-36.0%
Q4 24
19.0%
-22.1%
Q3 24
22.0%
-17.9%
Q2 24
6.9%
-34.6%
Q1 24
-1.3%
-71.4%
Capex Intensity
ALG
ALG
AXSM
AXSM
Q4 25
1.4%
0.0%
Q3 25
3.0%
0.0%
Q2 25
1.7%
0.0%
Q1 25
1.5%
0.3%
Q4 24
1.6%
0.0%
Q3 24
2.0%
0.1%
Q2 24
1.1%
0.1%
Q1 24
1.6%
0.1%
Cash Conversion
ALG
ALG
AXSM
AXSM
Q4 25
4.84×
Q3 25
2.58×
Q2 25
0.73×
Q1 25
0.45×
Q4 24
2.82×
Q3 24
3.51×
Q2 24
1.17×
Q1 24
0.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ALG
ALG

Wholegood Units$293.2M78%
Parts$61.6M16%
Other Revenue$18.9M5%

AXSM
AXSM

Segment breakdown not available.

Related Comparisons